Posted by Michael Wonder on 08 Jun 2022
CStone and Pfizer announce NMPA approval of sugemalimab in patients with unresectable stage III non-small cell lung cancer
6 June 2022 - Sugemalimab became the first anti-PD-1/PD-L1 monoclonal antibody approved for stage III NSCLC following concurrent or sequential chemoradiotherapy.
CStone Pharmaceuticals and Pfizer today announced that the NMPA of China has approved sugemalimab (Cejemly) for the treatment of patients with unresectable stage III non-small-cell lung cancer whose disease has not progressed following concurrent or sequential platinum-based chemoradiotherapy.
